表紙
市場調查報告書

HER2陰性乳癌:流行病學預測 ∼2028年

HER2-Negative Breast Cancer: Epidemiology Forecast to 2028

出版商 GlobalData 商品編碼 919452
出版日期 內容資訊 英文 61 Pages
訂單完成後即時交付
價格
Back to Top
HER2陰性乳癌:流行病學預測 ∼2028年 HER2-Negative Breast Cancer: Epidemiology Forecast to 2028
出版日期: 2019年11月29日內容資訊: 英文 61 Pages
簡介

本報告提供全球HER2陰性乳癌市場相關調查,主要8個市場 (美國、法國、德國、義大利、西班牙、英國、日本,及中國都市區) 的全濕潤性乳癌的風險因素、趨勢概要,各市場區隔的10年的流行病學預測等。

第1章 目錄

第2章 摘要整理

第3章 流行病學

  • 疾病的背景
  • 風險因素、合併症
  • 世界、過去趨勢
    • 美國
    • EU5個國家
    • 日本
    • 中國 (都市區)
  • 預測手法
    • 來源
    • 未使用的來源:EU5個國家
    • 預測的前提條件、手法
  • 流行病學預測
    • 發生數量:全浸潤性乳癌
    • 各年齡發生數量:全浸潤性乳癌
    • 發生數量:HER2-/HR+ 乳癌
    • 發生數量:TN乳癌
    • HER2-/HR+ 乳癌的發生數量的比例:各病期
    • TN乳癌的發生數量的比例:各病期
    • HER2-/HR+ 乳癌的發生數量:各閉經狀態
    • HER2-陰性乳癌的發生數量:PD-1 及 PD-L1 表現
    • BRCA變異伴隨的HER2-陰性乳癌的發生數量
    • PI3KCA變異伴隨的HER2-陰性乳癌的發生數量
    • HER2-陰性乳癌的發生數量:各骨轉移
    • 骨轉移/CNS轉移伴隨的HER2-陰性乳癌的發生數量
    • 5年的患病數量:全濕潤性乳癌
    • 5年的患病數量:HER2-陰性乳癌
    • 十年的患病數量:全濕潤性乳癌
    • 十年的患病數量:HER2-陰性乳癌
  • 討論

第4章 附錄

目錄
Product Code: GDHCER221-19

Breast cancer is a malignant tumor that originates in the breast tissue. Most breast cancers are invasive tumors that have grown beyond the ducts or lobules of the breast and can metastasize to other parts of the body through the bloodstream and the lymphatic system. HER2-/HR+ breast cancer are the most common form diagnosed in developed countries, making up approximately 75% of breast cancer cases in the US. TN breast cancer is another important subtype which makes up approximately 10% of the cases in the US.

GlobalData epidemiologists used age- and sex-specific diagnosed incidence and prevalence rates to forecast the diagnosed incident and prevalent cases, taking into account the significant relationship between age and HER2-negative incidence and prevalence. GlobalData epidemiologists applied country-specific incidence and prevalence rates of HER2-negative breast cancer, wherever available, to each country's population to obtain the number of estimated diagnosed incident and prevalent cases.

The following data describes epidemiology of HER2-negative breast cancer cases. In 2018, the 8MM had 679,991 diagnosed incident cases of HER2-negative breast cancer. This is expected to increase to 788,999 diagnosed incident cases by 2028, at an Annual Growth Rate (AGR) of 1.60%. This increase is partly attributed to the moderately rising trend in incidence in the 8MM, combined with underlying demographic changes in the respective markets. The 8MM will also see an increase in five-year diagnosed prevalent cases of HER2- negative breast cancer throughout the forecast period at an AGR of 0.88%, with 2,642,622 cases in 2018 and 2,874,871 in 2028. The development of more effective therapies, particularly for elderly patients, would improve survival from HER2-negative breast cancer.

Scope

  • HER2-Negative Breast Cancer Epidemiology Report provides an overview of the risk factors and global trends of all invasive breast Cancer in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Urban China).
  • This report also includes a 10-year epidemiological forecast for the following segmentations in ages 18 years and older across the 8MM: diagnosed incident cases of all invasive, HER2-/HR+, and HER2-/HR- triple negative (TN) breast cancer; diagnosed five -year and 10-year prevalent cases all invasive, HER2-/HR+, and TN breast cancer; and diagnosed incident cases of HER2-/HR+ and TN breast cancer by cancer staging (stage I -IV). Additionally, diagnosed incident cases of HER2-HR+ and TN breast cancer cases are further segmented by metastasis, and biomarker expression. HER2-/HR+ breast cancer cases are also segmented by menopausal status.
  • The HER2-Negative Breast Cancer Epidemiology Report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

The HER2-negative breast cancer Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global HER2-negative breast cancer market.
  • Quantify patient populations in the global HER2-negative breast cancer market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the cancer stages that present the best opportunities for HER2-negative breast cancer therapeutics in each of the markets covered.
  • Understand magnitude HER2-negative breast cancer market by subtypes such as biomarkers and distant metastasis.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 HER2-Negative Breast Cancer: Executive Summary

  • 2.1 Related Reports
  • 2.2 Upcoming Reports

3 Epidemiology

  • 3.1 Disease Background
  • 3.2 Risk Factors and Comorbidities
  • 3.3 Global and Historical Trends
    • 3.3.1 US
    • 3.3.2 5EU
    • 3.3.3 Japan
    • 3.3.4 China (Urban)
  • 3.4 Forecast Methodology
    • 3.4.1 Sources
    • 3.4.2 Sources Not Used - 5EU
    • 3.4.3 Forecast Assumptions and Methods
  • 3.5 Epidemiological Forecast for HER2-Negative Breast Cancer (2018-2028)
    • 3.5.1 Diagnosed Incident Cases of All Invasive Breast Cancer
    • 3.5.2 Age-Specific Diagnosed Incident Cases of All Invasive Breast Cancer
    • 3.5.3 Diagnosed Incident Cases of HER2-/HR+ Breast Cancer
    • 3.5.4 Diagnosed Incident Cases of TN Breast Cancer
    • 3.5.5 Proportion of Diagnosed Incident cases of HER2-/HR+ Breast Cancer by Stages
    • 3.5.6 Proportion of Diagnosed Incident cases of TN Breast Cancer by Stages
    • 3.5.7 Diagnosed Incident Cases of HER2-/HR+ Breast Cancer by Menopausal Status
    • 3.5.8 Diagnosed Incident cases of HER2-Negative Breast Cancer by PD-1 and PD-L1 Expression
    • 3.5.9 Diagnosed Incident Cases of HER2-Negative Breast Cancer with BRCA Mutation
    • 3.5.10 Diagnosed Incident Cases of HER2-Negative Breast Cancer with PI3KCA Mutation
    • 3.5.11 Diagnosed Incident Cases of HER2-Negative Breast Cancer by Bone Metastasis
    • 3.5.12 Diagnosed Incident Cases of HER2-Negative Breast Cancer with Brain/CNS Metastasis
    • 3.5.13 Five-Year Diagnosed Prevalent Cases of All Invasive Breast Cancer
    • 3.5.14 Five-Year Diagnosed Prevalent Cases of HER2-Negative Breast cancer
    • 3.5.15 10-Year Diagnosed Prevalent Cases of All Invasive Breast Cancer
    • 3.5.16 10-Year Diagnosed Prevalent Cases of HER2-Negative Breast cancer
  • 3.6 Discussion
    • 3.6.1 Epidemiological Forecast Insight
    • 3.6.2 Limitations of Analysis
    • 3.6.3 Strengths of Analysis

4 Appendix

List of Tables

  • Table 1: Risk Factors and Comorbidities for All Invasive Breast Cancer

List of Figures

  • Figure 1: 8MM, Diagnosed Incident Cases of HER2-Negative Breast Cancer, Women, Ages ≥18 Years, 2018 and 2028
  • Figure 2: 8MM, Diagnosed Incidence Rates of All Invasive Breast Cancer, Ages ≥18 Years, Women, Cases per 100,000 Population, 2008-2028
  • Figure 3: Sources Used for Diagnosed Incident Cases of All Invasive Breast Cancer
  • Figure 4: Sources Used for Diagnosed Incident Cases of HER2-/HR+ and TN Breast Cancer
  • Figure 5 : Sources Used for Diagnosed Incident Cases of HER2-/HR+ and TN Breast Cancer by Stage
  • Figure 6: Sources Used for Diagnosed Prevalent Cases of All Invasive Breast Cancer
  • Figure 7 : Diagnosed Incident Cases of All Invasive Breast Cancer, 8MM, Women, Ages ≥18 Years, 2018
  • Figure 8: 8MM, Age-Specific Diagnosed Incident Cases of All Invasive Breast Cancer, Women, Ages ≥18 Years, N, 2018
  • Figure 9: Diagnosed Incident Cases of HER2-/HR+ Breast Cancer, 8MM, Women, Ages ≥18 Years, N, 2018
  • Figure 10: Diagnosed Incident Cases of TN Breast Cancer, 8MM, Women, Ages ≥18 Years, N, 2018
  • Figure 11: Proportion of Diagnosed Incident Cases of HER2-/HR+ Breast Cancer by Stage, 8MM, Women, Ages ≥18 Years, N, 2018
  • Figure 12: Proportion of Diagnosed Incident Cases of TN Breast Cancer by Stage, 8MM, Women, Ages ≥18 Years, 2018
  • Figure 13: Proportion of HER2-/HR+ Breast Cancer by Menopausal Status, 8MM, Women, Ages ≥18 Years, 2018
  • Figure 14: HER2-Negative Breast Cancer by PD-1 and PD-L1 Expression, 8MM, Women, Ages ≥18 Years, 2018
  • Figure 15: Diagnosed Incident Cases of HER2-Negative Breast Cancer with BRCA Mutation, 8MM, Women, Ages ≥18 Years, 2018
  • Figure 16: HER2-Negative Breast Cancer by PI3K and AKT Mutation, 8MM, Women, Ages ≥18 Years, 2018
  • Figure 17: Diagnosed Incident Cases of HER2-Negative Breast Cancer by Bone Metastasis, 8MM, Women, Ages ≥18 Years, 2018
  • Figure 18: Diagnosed Incident Cases of HER2-Negative Breast Cancer with Brain/CNS Metastasis, 8MM, Women, Ages ≥18 Years, 2018
  • Figure 19 : Five-Year Diagnosed Prevalent Cases of All Invasive Breast Cancer, 8MM, Women, Ages ≥18 Years, 2018
  • Figure 20 : Five-Year Diagnosed Prevalent Cases of HER2-Negative Breast Cancer, 8MM, Women, Ages ≥18 Years, N, 2018
  • Figure 21 : 10-Year Diagnosed Prevalent Cases of All Invasive Breast Cancer, 8MM, Women, Ages ≥18 Years, N, 2018
  • Figure 22 : 10-Year Diagnosed Prevalent Cases of HER2-Negative Breast Cancer, 8MM, Women, Ages ≥18 Years, N, 2018
Back to Top